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To the Editor:
We read with great interest the arti-
cle by Bylicki et al.1 on the multimodal 
management of solitary fibrous tumors 
of the pleura (SFTP). The authors present 
a multi-institutional series of 68 patients 
with SFTP, spanning a wide spectrum of 
presentation from localized to metastatic 
disease. They describe in detail applied 
perioperative therapies and follow-up 
data to illustrate treatment efficacy, 
which unfortunately was limited. The 
authors also highlight the importance of 
the classification proposed by de Perrot et 
al.2 in the decision making for the admin-
istration of adjuvant therapies.
Excluding patients with metastatic 
disease (n = 9), there were 59 patients 
who underwent resection of SFTP as the 
primary treatment. Of these, five (8.5%) 
received perioperative treatments, 
mostly chemotherapy. Recurrence was 
observed in 18 (30.5%) patients with 
localized SFTP. Regardless of their 
stage classification, recurrence rates 
were extraordinarily high and not con-
gruent with previous published series 
(recurrence: 4–15%)2–5; this observation 
seemed driven by the recurrence of 52% 
in de Perrot stage II tumors, which may 
invoke the completeness of resection. 
Unfortunately, it is not possible to dis-
cern from the study how many patients 
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with localized SFTP underwent incom-
plete resection, and the impact this may 
have contributed to recurrence.
On the other hand, the authors 
stress the importance of the classification 
proposed by de Perrot et al.,2 not only as 
a prognostic factor but also as a guideline 
for adjuvant interventions. It should be 
noted that this classification was based 
on a nonsystematic literature review, and 
despite its prognostic value, corroborated 
by the authors1 and others, its validity to 
guide management after SFTP resection 
has yet to be proven. Moreover, manage-
ment recommendations derived from this 
classification2 were intended after com-
plete resection, as patients with incom-
plete resections are at a higher risk for 
recurrence. Therefore, it is not surprising 
that adjuvant chemotherapy was given to 
six of seven patients with tumor invasion 
at the resection margins, regardless of 
their de Perrot classification.
Recently, a scoring system was pro-
posed for the prediction of SFTP recur-
rence after complete resection3 and was 
later validated in an independent European 
population.4 This score combines six 
macroscopic and histopathologic tumor 
characteristics to classify patients accord-
ing to their risk of recurrence with excel-
lent predictive capacity, outperforming 
both the use of England’s criteria and de 
Perrot’s classification. A recent indepen-
dent, multi-institutional series of patients 
with SFTP5 found this scoring system to 
provide better discrimination compared 
with previously published classifications. 
In addition, this score has been associated 
with the extent of surgery, use of adjuvant 
therapies, and overall survival.4 This scor-
ing system was first published in 20133 
and should be carefully considered by the 
authors to assess risk of recurrence in the 
analysis of their patient population. Better 
prognostic models, such as the one men-
tioned here,3,4 may result in better stratifi-
cation of patients according to their risk of 
recurrence. This would result in improved 
selection of those patients at the highest 
risk for SFTP recurrence for adjuvant 
interventions, clinical trials, or stricter 
postoperative surveillance protocols.
Luis F. Tapias, MD
Michael Lanuti, MD
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In Response:
We would like to thank Dr. 
Tapias and Dr. Lanuti for their 
The response below published pre-
viously in the June 2015 issue. It is 
republished below to appear  
with the Letter to the Editor by  
Drs. Tapias and Lanuti.
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As cancer epidemiologists, we 
read the article by Baumann et al.1 
with great interest. We praise Baumann 
for producing a body of literature on 
mesothelioma and exposure to natu-
ral-occurring asbestos (NOA).2–4 The 
recent discovery of NOA in Southern 
Nevada has raised our interest in the 
surveillance of mesothelioma in the 
region.
Unfortunately, in our opinion, 
the methodology used was inappro-
priate for the stated aim of the study: 
“to test that malignant mesothelioma 
is increased in Southern Nevada in a 
pattern consistent with environmen-
tal exposure.” The proper indicator of 
risk in a population or a subpopula-
tion is the incidence rate (gender spe-
cific, age adjusted, and/or age specific). 
Proportions or sex ratios restricted to 
mesothelioma deaths are not appropri-
ate measures of risk because they do 
not account for the underlying popu-
lation pool (and the concept of risk in 
epidemiology) from which the cases 
arise. For instance, a male to female sex 
ratio can be elevated just by virtue of a 
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comments on our recent article report-
ing on a multicenter cohort of 68 
patients with solitary fibrous tumors 
of the pleura (SFTP), who were ana-
lyzed for the complete course of the 
disease in a routine practice setting.1 
We acknowledge that our recurrence 
rate of 30% in nonmetastatic dis-
ease was higher than that previously 
reported in surgical series, includ-
ing that by Tapias et al.2 (14%). We 
hypothesize this may be related to (1) 
a more limited enrollment period (12 
years from 2000 to 2012, versus 33 
years from 1977 to 2010 in the Tapias 
series) together with (2) a prolonged 
median follow-up of 13 years and (3) 
the recruitment of cases from medi-
cal oncology services, at an advanced 
stage of the disease then requiring 
chemotherapy treatment.1 We agree 
that incomplete resection may have 
contributed to this higher recurrence 
rate, as five patients—four stage II 
tumors, one stage III tumor—had 
R1 resection, and two patients—
both stage III—had R2 resection. 
We believe this reflects routine prac-
tice, as other surgical series simi-
larly reported incomplete resection 
to occur in 7% to 11% of malignant 
SFTP.3
On the basis of their series of 
59 patients, Tapias et al. propose 
a scoring system to predict SFTP 
recurrences; four of the six variables 
of this scoring are actually common 
with that of the England/de Perrot 
staging, including structure, mitotic 
activity, cellularity, and presence of 
necrosis.2 Of note, Tapias et al. did 
not applied the de Perrot staging to 
their cases, whereas they stated that 
scoring was a superior predictor of 
recurrence.
Comparing our cohort with this 
series, scores had the following distri-
bution: 0 in 15% versus 42% patients, 
1 in 13% versus 19%, 2 in 28% versus 
19%, 3 in 19% versus 12%, 4 in 7% 
versus 5%, 5 in 9% versus 3%, and 
6 points in 9% versus 0%. Scoring, 
although correlating with the de Perrot 
stage (p < 0.001), was also a sig-
nificant predictor of recurrence-free 
survival (p = 0.007): 3-year, 5-year, 
10-year, and 15-year recurrence-free 
survival rates were 40%, 31%, 25%, 
and 25%, respectively, for a score 
≥3, and 88%, 70%, 58%, and 58%, 
respectively, for a score <3. These fig-
ures are far lower than that reported in 
the original series by Tapias et al.—
80%, 69%, 23%, and 23% for a score 
≥3 and 100% for a score of <3—and 
in a more recent validation cohort.5 
This reflects the higher aggressive-
ness of our cases that would be even 
more appreciated using the proposed 
6-class score, which may be even 
more relevant for advanced malignant 
cases. Whether these analyses are rel-
evant to drive perioperative manage-
ment still remains to be determined, 
especially because the efficacy of 
adjuvant treatment is limited, as high-
lighted in our cohort.
Ultimately, such major differ-
ences between reported series of TFSPs 
emphasize the need for multicenter col-
laboration to develop prospective obser-
vational cohorts of consecutive patients, 
what remains challenging given the 
wide range of aggressiveness of the dis-
ease, the long-term survival of patients, 
and the multidisciplinary management 
from initial presentation to recurrent 
disease.
Olivier Bylicki, MD
Nicolas Girard, MD, PhD
Respiratory Medicine and Thoracic 
Oncology Service
Hôpital Louis Pradel, 
Hospices Civils de Lyon
Lyon, France 
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